MAPK3 and adenoma: It is not clear whether other negative regulators are involved in the inactivation of ERK1/2 in adenomas harboring Kras mutations in this mouse model, but the absence of pERK1/2 in NNK‐induced adenomas suggests that regulatory mechanisms of ERK1/2 phosphorylation may function in lung precancerous lesions.